Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13069284 | 1.00 | MAOB (0.42) | MAOBMAOALMNASLC6A2SLC6A4 | |
| SCHEMBL13224950 | 1.00 | MAOB (0.42) | MAOBMAOALMNASLC6A2SLC6A4 | |
| SCHEMBL14520914 | 1.00 | MAOB (0.42) | MAOBMAOALMNASLC6A2SLC6A4 | |
| SCHEMBL6003737 | 1.00 | MAOB (0.42) | MAOBMAOALMNASLC6A2SLC6A4 | |
| SCHEMBL14520912 | 1.00 | MAOB (0.42) | MAOBMAOALMNASLC6A2SLC6A4 | |
| SCHEMBL6003734 | 1.00 | MAOB (0.42) | MAOBMAOALMNASLC6A2SLC6A4 | |
| SCHEMBL14520919 | 0.86 | OPRK1 (0.42) | MAOBMAOALMNASLC6A2SLC6A4 | |
| SCHEMBL13069788 | 0.83 | MAOB (0.38) | MAOBSLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL2712202 | 0.83 | MEN1 (0.41) | MAOBSLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL13069369 | 0.83 | MAOB (0.42) | MAOBMAOALMNASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| WO-2007014264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | MAOB 2096/4885MAOA 1725/4885LMNA 1263/4885 |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | MAOB 22/4885MAOA 71/4885LMNA 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.